ZS Launches ZAIDYN™ Clinical Development, Expanding Its Digital Life Sciences Platform
17.6.2022 16:45:00 EEST | Business Wire | Press release
Global management consulting and technology firm ZS has announced the launch of ZAIDYN Clinical Development. The offering is the latest expansion of the platform ZAIDYN by ZS, designed to empower life sciences companies to digitally transform and scale customer engagement, field performance, analytics and—now—clinical development design and planning.
“Today, we’re announcing the launch of ZAIDYN Clinical Development, expanding on more than 35 years of software expertise,” said Sanjay Joshi, managing principal and platform lead for ZS. “With ZAIDYN, life sciences organizations can connect their global teams, products, processes, applications, algorithms and data assets for powerful insights to shape clinical research and accelerate clinical development timelines. Our platform works with existing IT systems to fuel efficiency and connectivity, reduce costs and empower life sciences companies of all sizes to innovate, scale and grow as the global healthcare ecosystem evolves.”
ZAIDYN Clinical Development harnesses the power of a self-learning network, AI-driven insights and algorithms to create a fluid, fast, frictionless trial experience for business users, site investigators and patients. With our products, companies have the power to:
- Drive innovation and decision-making throughout the clinical development process with insightful, dynamic reporting and analytics for clinical teams and a high-level view of clinical trial operations for leaders
- Optimize clinical study planning and protocol design using AI and predictive insights that reflect the experiences and perspectives of participants and patients
- Empower teams to test and model site and enrollment scenarios to find ways to make studies more inclusive and engaging, lift participant burden, limit amendments and accelerate trial efficiency
- Create an expanding universe of industry and historical clinical trial data, real-world data, site criteria and patient survey insights
- Raise the bar for clinical research with products built on Amazon Web Services (AWS) that apply the latest clinical data standards and fuel connectivity throughout upstream and downstream systems
More than 130 companies already use ZS’s products to drive business decisions. Now, these companies can combine the clinical expertise of ZS consulting with the latest features of ZAIDYN Clinical Development to break down business and clinical silos and empower teams to work together more efficiently.
“ZAIDYN Clinical Development will help our clients navigate the large-scale, disruptive changes we see happening across our industry—and those on the horizon as AI and machine learning transform clinical research and development (R&D),” said Aaron Mitchell, ZS’s global R&D excellence practice leader. “Smarter platforms for life sciences can help us improve clinical trial diversity, bring life-saving therapies to patients faster, and unlock patterns and breakthroughs that will transform the future of clinical research. It’s all about using insights from data more effectively to drive more inclusive studies and better patient outcomes.”
“With the support of ZS and the ZAIDYN platform, we’re accelerating the transformation we initiated three years ago,” reflected Cynthia Deparis, program manager at Sanofi. “The platform is helping us take a data-driven approach to identifying the best countries and sites for clinical studies. It’s helped us integrate and expand the universe of clinical operational trial data so we can target sites and countries that help us deliver on our development portfolio and think through various strategic parameters like the competitive landscape, our peers’ activity, historical knowledge about sites and feedback from outreached sites. With these insights and the ability to model different scenarios, we can continue to optimize recruitment and enhance the accuracy of our projections, setting our clinical trial development on a continuous improvement cycle.”
About ZS
ZS is a management consulting and technology firm focused on transforming global healthcare and beyond. We leverage our leading-edge analytics, plus the power of data, science and products to help our clients make more intelligent decisions, deliver innovative solutions and improve outcomes for all. Founded in 1983, ZS has more than 12,000 employees in 35 offices worldwide. To learn more, visit www.zs.com or follow us on Twitter and LinkedIn.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220617005012/en/
Contact information
Quintin Maidment; ZS@theblissgrp.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 21:00:00 EET | Press release
Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham, MSc, MD, FRCPC, dermatologist, SKiN Centre for Dermatology, Peterborough, Ontario, Canada, principal investigator for the Latitude PsO studies and presenting author. “These efficacy and safety results show it’s possible for a once-daily pill to deliver rapid, lasting skin clearance, highlighting the potential of zasoc
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 21:00:00 EET | Press release
Incyte (Nasdaq:INCY) today announced 54-week data evaluating the safety and efficacy of povorcitinib (INCB54707), an oral small-molecule highly-selective JAK1 inhibitor, from the pivotal Phase 3 STOP-HS clinical trial program in adult patients (≥18 years) with moderate to severe hidradenitis suppurativa (HS). The late-breaking oral presentation of these data is taking place at the 2026 American Academy of Dermatology (AAD) Annual Meeting, being held March 27-31, 2026, in Denver (Session: S034 – Late-Breaking Research: Session 2. Saturday, March 28, 2026, 1:00-4:00 p.m. MT). “The 54-week results from the STOP-HS program deliver compelling, long-term evidence supporting the potential of povorcitinib for patients with moderate to severe HS,” said Pablo J. Cagnoni, M.D., President and Global Head of Research and Development, Incyte. “Across both studies, povorcitinib demonstrated substantial and durable improvements over time in key measures of treatment success and meaningful clinical ben
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 17:00:00 EET | Press release
Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-breaking session at the 2026 American Academy of Dermatology (AAD) Annual Meeting. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260328320362/en/ Atopic dermatitis is the most common inflammatory skin disorder in children, yet treatment options in the moderate-to-severe pediatric setting are limited.5 The disease can have a significant impact on quality of life for both the patients and their loved ones, with persistent itch and recurrent skin lesions often disrupting sleep, school and relationships.5-8 “Atopic dermatitis can affect many aspects of children’s lives including schoolwork, emotional development
Angelalign Technology (6699.HK) Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 21:56:00 EET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 19:46:00 EET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom